A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure

There is a strong association between Guillain-Barre syndrome (GBS) and Penner's serotype 19 (PEN 19) of Campylobacter jejuni. Sera from patients with GBS after C. jejuni infection have autoantibodies to GM1 ganglioside in the acute phase of the illness. Our previous work has suggested that GBS results from an immune response to cross-reactive antigen between lipopolysaccharide (LPS) of the Gram-negative bacterium and membrane components of peripheral nerves. To clarify the pathogenesis of GBS, we have investigated whether GM1-oligosaccharide structure is present in the LPS of C. jejuni (PEN 19) that was isolated from a GBS patient. After extraction of the LPS, the LPS showing the binding activity of cholera toxin, that specifically recognizes the GM1- oligosaccharide was purified by a silica bead column chromatography. Gas-liquid chromatography-mass spectrometric analysis has shown that the purified LPS contained Gal, GalNAc, and NeuAc, which are sugar components of GM1 ganglioside. 1H NMR methods [Carr-Purcell-Meiboom- Gill (CPMG), total correlation spectroscopy (TOCSY), and nuclear Overhauser effect spectroscopy (NOESY)] have revealed that the oligosaccharide structure [Gal beta 1-3 GalNAc beta 1-4(NeuAc alpha 2- 3)Gal beta] protrude from the LPS core. This terminal structure [Gal beta 1-3GalNAc beta 1-4(NeuAc alpha 2-3)Gal beta] is identical to the terminal tetrasaccharide of the GM1 ganglioside. This is the first study to demonstrate the existence of molecular mimicry between nerve tissue and the infectious agent that elicits GBS.

• Publication year

  1993

• Venue

  Journal of Experimental Medicine

• Publication date

  1993-11-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1084/JEM.178.5.1771PMID 8228822PMCID 2191246
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Experimental autoimmune neuropathy with anti-GM1 antibodies and immunoglobulin deposits at the nodes of Ranvier

  2004cited by this paper
• Campylobacter jejuni strains from patients with guillain‐barré syndrome belong mostly to penner serogrpup 19 and contain β‐N‐acetylglucosamine residues

  1993cited by this paper
• Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues.

  1993cited by this paper
• Chemical structures of the core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipopolysaccharides.

  1993cited by this paper
• Chemical structure of the core region of Campylobacter jejuni serotype O:2 lipopolysaccharide.

  1993cited by this paper
• Serum and CSF anti-GM1 antibodies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.

  1993cited by this paper
• Serological diversity and chemical structures of Campylobacter jejuni low-molecular-weight lipopolysaccharides

  1992cited by this paper
• Guillain-Barré syndrome associated with high titers of anti-GM1 antibodies.

  1992cited by this paper
• Cross-reactive antigen between nervous tissue and a bacterium elicits Guillain-Barre syndrome : molecular mimicry between ganglioside GM1 and lipopolysaccharide from Penner's serotype 19 of Campylobacter jejuni

  1992cited by this paper
• Serotype of Campylobacter jejuni, HLA, and the Guillain-Barré syndrome.

  1992cited by this paper
• The Guillain-Barré syndrome.

  1992cited by this paper
• Bovine gangliosides and acute motor polyneuropathy.

  1992cited by this paper
• Structural analysis of oligosaccharide chains of glycolipids by two‐dimensional NMR

  1992cited by this paper
• Chemical characterization of Campylobacter jejuni lipopolysaccharides containing N-acetylneuraminic acid and 2,3-diamino-2,3-dideoxy-D-glucose

  1991cited by this paper
• Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome.

  1991cited by this paper
• Early events of chemical transmission of newly formed neuromuscular junctions in monolayers of human muscle cells co-cultured with fetal rat spinal cord explants.

  1991cited by this paper
• HLA‐B35 and acute axonal polyneuropathy following Campylobacter infection

  1991cited by this paper
• Guillain-Barré syndrome and parenteral gangliosides

  1991cited by this paper
• The role of the O antigen in adjuvant activity of lipopolysaccharide.

  1991cited by this paper
• Guillain-Barré syndrome and parenteral gangliosides.

  1991cited by this paper
• Acute axonal polyneuropathy associated with anti‐GM1 antibodies following Campylobacter enteritis

  1990cited by this paper
• Immunostaining of motor nerve terminals by IgM M protein with activity against gangliosides GM1 and GDlb from a patient with motor neuron disease

  1988cited by this paper
• A prospective study of acute idiopathic neuropathy. II. Antecedent events.

  1988cited by this paper
• Analysis of NMR spectra of sugar chains of glycolipids by multiple relayed COSY and 2D homonuclear

  1987cited by this paper
• A rapid and sensitive method for the analysis of carbohydrate components in glycoproteins using gas-liquid chromatography.

  1982cited by this paper
• Passive hemagglutination technique for serotyping Campylobacter fetus subsp. jejuni on the basis of soluble heat-stable antigens

  1980cited by this paper
• Ganglioside syndrome, a new autoimmune neurologic disorder, experimentally induced with brain gangliosides.

  1976cited by this paper
• Über die Extraktion von Bakterien mit Phenol/Wasser

  1952cited by this paper

• Critical insights for intensivists on Guillain-Barré syndrome

  2025cites this paper
• Post-Infectious Guillain-Barré Syndrome During a Cholera Outbreak in Yemen: A Paediatric Case with Confirmed Campylobacter Exposure.

  2025cites this paper
• Acute Motor Axon Neuropathy that Improved One Year After Onset: A Case Report

  2025cites this paper
• Atypical Guillain-Barré Syndrome in a Pediatric Patient With a Preceding Non-COVID-19 Coronavirus Infection: A Case Report

  2024cites this paper
• Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial

  2024influential citation
• Guillain–Barre syndrome and link with COVID-19 infection and vaccination: a review of literature

  2024cites this paper
• A Neuropathy Mimic: Statin-Induced Myopathy Presenting as Guillain-Barré Syndrome

  2024cites this paper
• The gut-retina axis: Uncovering the role of autoimmunity in glaucoma development

  2024cites this paper
• Pathogenicity and virulence of Campylobacter jejuni: What do we really know?

  2024cites this paper
• Activation of the l-fucose utilization cluster in Campylobacter jejuni induces proteomic changes and enhances Caco-2 cell invasion and fibronectin binding

  2024cites this paper
• Consortium of Lactobacillus crispatus 2029 and Ligilactobacillus salivarius 7247 Strains Shows In Vitro Bactericidal Effect on Campylobacter jejuni and, in Combination with Prebiotic, Protects Against Intestinal Barrier Dysfunction

  2024cites this paper
• Guillain–Barre syndrome complicating knee infectious arthritis

  2023cites this paper
• Origins and immunopathogenesis of autoimmune central nervous system disorders

  2023cites this paper
• Clinical Accent and Outcomes of the Guillain - Barre Syndrome (Acute Inflammatory Demyelinating Polyradiculoneuropathy)

  2023cites this paper
• Immune-Mediated Neuropathies: Pathophysiology and Management

  2023cites this paper
• Therapeutic issues in Guillain–Barré syndrome

  2023cites this paper
• SERUM ALBUMIN: AN INDEPENDENT INDICATOR IN GUILLAIN–BARRE SYNDROME PATIENTS RECEIVING TREATMENT OF PLASMAPHERESIS

  2023cites this paper
• Seroprevalence of Campylobacter jejuni infection in common subtypes of Guillain–Barre syndrome in Kashmiri population

  2023cites this paper
• Antibodies to Glycolipids in Guillain-Barré Syndrome, Miller Fisher Syndrome and Related Autoimmune Neurological Diseases.

  2023cites this paper
• The distribution of heterophilic antigens and their relationship with autoimmune diseases

  2023cites this paper
• Molecular, Electrophysiological, and Ultrasonographic Differences in Selected Immune-Mediated Neuropathies with Therapeutic Implications

  2023cites this paper
• Recurrent Guillain-Barré Syndrome Associated with the Second Episode of Campylobacter jejuni Infection

  2023influential citation
• Th1/Th17-mediated Immunity and Protection from Peripheral Neuropathy in Wildtype and IL10-/- BALB/c Mice Infected with a Guillain-Barré Syndrome‑associated Campylobacter jejuni Strain.

  2022cites this paper
• Campylobacter jejuni and Postinfectious Autoimmune Diseases: A Proof of Concept in Glycobiology.

  2022cites this paper
• CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention

  2022cites this paper
• Pragmatic guide to peripheral nerve disease and the role of clinical biomarkers

  2022cites this paper
• Guillain-Barré Syndrome after Capnocytophaga canimorsus infection with class-switch of anti-ganglioside antibodies

  2022cites this paper
• Guillain-Barre syndrome complicating Neisseria meningitidis infection.

  2022cites this paper
• Electromyographic Findings in Guillain-Barré Syndrome Patients

  2022cites this paper
• Successful treatment with therapeutic plasmapheresis of a pediatric patient with Guillain‐Barré syndrome associated with neurobrucellosis

  2022cites this paper
• Campylobacter jejuni Infection, Anti-Ganglioside Antibodies, and Neuropathy

  2022cites this paper
• Role of inhibitory B cell co‐receptors in B cell self‐tolerance to non‐protein antigens *

  2022cites this paper
• B cells in the balance: Offsetting self-reactivity avoidance with protection against foreign

  2022cites this paper
• Ophthalmoplegia associated with anti-GQ1b antibodies: case report and review

  2021cites this paper
• Bioengineering of LAB vector expressing Haemolysin co-regulated protein (Hcp): a strategic approach to control gut colonization of Campylobacter jejuni in a murine model

  2021cites this paper
• Therapeutic plasma exchange as a first-choice therapy for axonal Guillain-Barré syndrome: A case-based review of the literature (Review)

  2021cites this paper
• Characteristics of Guillain-Barré syndrome in a Lebanese tertiary care center.

  2021cites this paper
• Revisiting Campylobacter jejuni Virulence and Fitness Factors: Role in Sensing, Adapting, and Competing

  2021cites this paper
• The role of antibodies to peripheral nerve antigens in pathogenesis and laboratory evaluation of immune-mediated neuropathies

  2021cites this paper
• Multifaceted features of immunoglobulin G anti‐GM1 antibodies in Guillain–Barré syndrome

  2021cites this paper
• Guillain–Barré syndrome: pathophysiology, etiology, causes, and treatment

  2021cites this paper
• [The prognosis and prognostic factor of Guillain-Barré Syndrome].

  2020cites this paper
• Autoimmune Peripheral Neuropathies and Contribution of Antiganglioside/Sulphatide Autoantibody Testing

  2020cites this paper
• Helicobacter pylori and Immune-mediated Disorders

  2020cites this paper
• GalCer: Galactocerebroside GBS: Guillain-Barré syndrome IMPN: Immune-mediated polyneurop- athy IVIg: Intravenous immunoglobulin MAG: Myelin-associated glycoprotein MFS: Miller Fisher syndrome MMN: Multifocal motor neuropathy PCB: Pharyngeal-cervical brachial variant of GBS Autoimmune Peripheral Neu

  2020cites this paper
• Inflammatory polyradiculoneuropathies: Clinical and immunological aspects, current therapies, and future perspectives

  2020cites this paper
• Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective

  2020cites this paper
• Germinal centers and autoantibodies

  2020cites this paper
• Neurological disorders-associated anti-glycosphingolipid IgG-antibodies display differentially restricted IgG subclass distribution

  2020cites this paper
• Comparative Pathology of the Peripheral Nervous System

  2020cites this paper
• Progress Towards the Development of Glycan-Based Vaccines against Campylobacteriosis.

  2020cites this paper
• Axonal variants of Guillain–Barré syndrome: an update

  2020cites this paper
• Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels

  2020cites this paper
• An antibiotic depleted microbiome drives severe Campylobacter jejuni-mediated Type 1/17 colitis, Type 2 autoimmunity and neurologic sequelae in a mouse model.

  2019cites this paper
• Most of anti-glycolipid IgG-antibodies associated to neurological disorders occur without their IgM counterpart

  2019cites this paper
• Phase-variable bacterial loci: how bacteria gamble to maximise fitness in changing environments.

  2019cites this paper
• Minding the gap: The impact of B‐cell tolerance on the microbial antibody repertoire

  2019cites this paper
• Guillain-Barré and Alpha-gal Syndromes: Saccharides-induced Immune Responses

  2019cites this paper
• Recent Concepts of Guillain-Barré Syndrome

  2019cites this paper
• Antecedent infections in Guillain‐Barré syndrome: a single‐center, prospective study

  2019cites this paper
• Role of putative virulence traits of Campylobacter jejuni in regulating differential host immune responses

  2019cites this paper
• Guillain Barre Syndrome

  2019cites this paper
• Guillain–Barre Syndrome

  2019cites this paper
• Guillain–Barré症候群/慢性炎症性脱髄性多発根ニューロパチーの自己抗体：糖脂質抗体

  2019cites this paper
• The Roles of Peyer's Patches and Microfold Cells in the Gut Immune System: Relevance to Autoimmune Diseases

  2019cites this paper
• Bacterial AB5 toxins inhibit the growth of gut bacteria by targeting ganglioside-like glycoconjugates

  2019cites this paper
• The origin and genetic basis of nonulosonic acid biosynthesis in Campylobacter coli lipooligosaccharides

  2018influential citation
• Immunoproteomic identification of antigenic candidate Campylobacter jejuni and human peripheral nerve proteins involved in Guillain-Barré syndrome.

  2018cites this paper
• [Viewing sepsis and autoimmune disease in relation with infection and NETs-formation].

  2018cites this paper
• CHAPTER 1: Literature review

  2018cites this paper
• Experimental approach in research of Guillain–Barré syndrome: A range of pathogeneses mediated by molecular mimicry

  2018cites this paper
• Amendment history : Erratum ( December 1999 ) Monoclonal antibodies raised against Guillain-Barré syndrome – associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations

  2018influential citation
• Anti-ganglioside Antibodies in Peripheral Nerve Pathology.

  2018cites this paper
• Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction

  2018cites this paper
• Acute flaccid paralysis: An approach to diagnosis

  2017cites this paper
• Syndrome de Guillain-Barré

  2017cites this paper
• Immunopathogenesis and Treatment of Guillain-Barre Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy

  2017cites this paper
• The Ability of Select Probiotics to Reduce Enteric Campylobacter Colonization in Broiler Chickens.

  2017influential citation
• The immunopathology of dengue and Zika virus infections.

  2017cites this paper
• Development of new ganglioside probes and unraveling of raft domain structure by single-molecule imaging.

  2017cites this paper
• Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases

  2017cites this paper
• Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis

  2017cites this paper
• Effects of antibiotic resistance (AR) and microbiota shifts on Campylobacter jejuni-mediated diseases

  2017cites this paper
• Postinfection Irritable Bowel Syndrome: The Links Between Gastroenteritis, Inflammation, the Microbiome, and Functional Disease

  2017cites this paper
• Guillain‐Barré Syndrome

  2017cites this paper
• Strategien zur Subklassifizierung Guillain-Barré-artiger Polyneuropathien bei Hund und Katze

  2017cites this paper
• Workflow : Annotated pdf , CrossRef and tracked changes PROOF COVER SHEET

  2016cites this paper
• Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae.

  2016cites this paper
• Guillain–Barré Syndrome and Campylobacter jejuni Enteritis

  2016cites this paper
• Association of NOD1 and NOD2 polymorphisms with Guillain-Barré syndrome in Northern Indian population.

  2016cites this paper
• Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl.

  2016cites this paper
• Guillain–Barré syndrome: a century of progress

  2016cites this paper
• Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment

  2016cites this paper
• Understanding the pathogenesis of guillain-barre syndrome through neurophysiology and serological analyses / Nortina Shahrizaila

  2016cites this paper
• Guillain-Barré syndrome: What have we learnt during one century? A personal historical perspective.

  2016cites this paper
• Isolierungsraten, Resistenzverhalten und genetische Diversität von Campylobacter aus Tierbeständen und Umwelthabitaten

  2016cites this paper
• Serial electrophysiological findings in Guillain–Barré syndrome not fulfilling AIDP or AMAN criteria

  2016cites this paper
• Characterisation of the Campylobacter jejuni PEB3 and GlpT

  2016cites this paper
• Campylobacter infections and Guillain Barré syndrome

  2015cites this paper
• Guillain Barré syndrome (GBS): new insights in the molecular mimicry between C. jejuni and human peripheral nerve (HPN) proteins.

  2015cites this paper